Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
24 mars 2022 08h00 HE
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort ...
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
08 mars 2022 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Clinical and Preclinical Program Updates
15 févr. 2022 08h05 HE
|
Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...
Monopar to Present at the H.C. Wainwright BioConnect Conference
07 janv. 2022 07h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial
08 déc. 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
12 nov. 2021 08h00 HE
|
Monopar Therapeutics Inc.
First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe andon Track for Reaching Interim in H1 2022 WILMETTE, Ill., Nov. 12,...
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
27 oct. 2021 08h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
16 sept. 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
13 sept. 2021 08h00 HE
|
Monopar Therapeutics Inc.
Trial launch in Europe coincides with the Company’s upcoming presentation at the European Society for Medical Oncology Congress WILMETTE, Ill., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Monopar...
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
09 sept. 2021 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...